Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Baxter
Boehringer Ingelheim
Harvard Business School
Colorcon

Last Updated: July 3, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021055


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

NDA 021055 describes TARGRETIN, which is a drug marketed by Valeant Luxembourg and Bausch and is included in two NDAs. It is available from two suppliers. Additional details are available on the TARGRETIN profile page.

The generic ingredient in TARGRETIN is bexarotene. There are seven drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the bexarotene profile page.
Summary for 021055
Tradename:TARGRETIN
Applicant:Valeant Luxembourg
Ingredient:bexarotene
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 021055
Suppliers and Packaging for NDA: 021055
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TARGRETIN bexarotene CAPSULE;ORAL 021055 NDA Bausch Health US, LLC 0187-5526 0187-5526-75 1 BOTTLE in 1 CARTON (0187-5526-75) > 100 CAPSULE, LIQUID FILLED in 1 BOTTLE
TARGRETIN bexarotene CAPSULE;ORAL 021055 NDA AUTHORIZED GENERIC Oceanside Pharmaceuticals 68682-003 68682-003-10 1 BOTTLE in 1 CARTON (68682-003-10) > 100 CAPSULE, LIQUID FILLED in 1 BOTTLE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength75MG
Approval Date:Dec 29, 1999TE:ABRLD:Yes

Expired US Patents for NDA 021055

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Luxembourg TARGRETIN bexarotene CAPSULE;ORAL 021055-001 Dec 29, 1999   Start Trial   Start Trial
Valeant Luxembourg TARGRETIN bexarotene CAPSULE;ORAL 021055-001 Dec 29, 1999   Start Trial   Start Trial
Valeant Luxembourg TARGRETIN bexarotene CAPSULE;ORAL 021055-001 Dec 29, 1999   Start Trial   Start Trial
Valeant Luxembourg TARGRETIN bexarotene CAPSULE;ORAL 021055-001 Dec 29, 1999   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
Baxter
Boehringer Ingelheim
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.